Quantitative analysis of polymorphic mixtures of ranitidine hydrochloride by raman spectroscopy and principal components analysis
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Quantitative analysis of polymorphic mixtures of ranitidine hydrochloride by raman spectroscopy and principal components analysis. / Pratiwi, Destari; Paul Fawcett, J.; Gordon, Keith C.; Rades, Thomas.
In: European Journal of Pharmaceutics and Biopharmaceutics, Vol. 54, No. 3, 11.2002, p. 337-341.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Quantitative analysis of polymorphic mixtures of ranitidine hydrochloride by raman spectroscopy and principal components analysis
AU - Pratiwi, Destari
AU - Paul Fawcett, J.
AU - Gordon, Keith C.
AU - Rades, Thomas
PY - 2002/11
Y1 - 2002/11
N2 - Ranitidine hydrochloride exists as two polymorphs, forms I and II, both of which are used to manufacture commercial tablets. Raman spectroscopy can be used to differentiate the two forms but univariate methods of quantitative analysis of one polymorph as an impurity in the other lack sensitivity. We have applied principal components analysis (PCA) of Raman spectra to binary mixtures of the two polymorphs and to binary mixtures prepared by adding one polymorph to powdered tablets of the other. Based on absorption measurements of seven spectral regions, it was found that >97% of the spectral variation was accounted for by three principal components. Quantitative calibration models generated by multiple linear regression predicted a detection limit and quantitation limit for either forms I or II in mixtures of the two of 0.6 and 1.8%, respectively. This study demonstrates that PCA of Raman spectroscopic data provides a sensitive method for the quantitative analysis of polymorphic impurities of drugs in commercial tablets with a quantitation limit of less than 2%.
AB - Ranitidine hydrochloride exists as two polymorphs, forms I and II, both of which are used to manufacture commercial tablets. Raman spectroscopy can be used to differentiate the two forms but univariate methods of quantitative analysis of one polymorph as an impurity in the other lack sensitivity. We have applied principal components analysis (PCA) of Raman spectra to binary mixtures of the two polymorphs and to binary mixtures prepared by adding one polymorph to powdered tablets of the other. Based on absorption measurements of seven spectral regions, it was found that >97% of the spectral variation was accounted for by three principal components. Quantitative calibration models generated by multiple linear regression predicted a detection limit and quantitation limit for either forms I or II in mixtures of the two of 0.6 and 1.8%, respectively. This study demonstrates that PCA of Raman spectroscopic data provides a sensitive method for the quantitative analysis of polymorphic impurities of drugs in commercial tablets with a quantitation limit of less than 2%.
KW - Polymorphism
KW - Principal components analysis
KW - Quantitative analysis
KW - Raman spectroscopy
KW - Ranitidine-HCl
UR - http://www.scopus.com/inward/record.url?scp=0036848589&partnerID=8YFLogxK
U2 - 10.1016/S0939-6411(02)00113-3
DO - 10.1016/S0939-6411(02)00113-3
M3 - Journal article
C2 - 12445565
AN - SCOPUS:0036848589
VL - 54
SP - 337
EP - 341
JO - European Journal of Pharmaceutics and Biopharmaceutics
JF - European Journal of Pharmaceutics and Biopharmaceutics
SN - 0939-6411
IS - 3
ER -
ID: 299430095